Analysts' Actions: BIIB CLMT GPOR ORIG

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

athenahealth was initiated with a neutral rating at Sterne Agee. $84 price target. Valuation is fair, Sterne Agee said.

Audience ( ADNC) was initiated with a hold rating at TheStreet Ratings.

Biogen Idec ( BIIB) was downgraded at Citigroup to neutral from buy. Price target is $236. There is risk that regulatory data protection for the company's flagship MS drug, Tecfidera, is limiting valuation, Citi said.

Bob Evans Farms ( NOK) was initiated with an overweight rating and $57 price target at Oppenheimer. Both the restaurant and grocery businesses are emerging from transformational initiatives, improving performance, Oppenheimer said.

Calumet Specialty Products ( CLMT) was initiated with an outperform rating and $40 price target at Credit Suisse. Geographical and product diversity should provide solid distribution growth, Credit Suisse said.

Gulfport Energy ( GPOR) coverage was reinstated at Credit Suisse with an outperform rating and $72 price target. Additional Utica inventory and a quicker than anticipated ramp to a seven-rig program will drive upside, Credit Suisse said.

Allscripts Healthcare Solutions ( MDRX) was initiated with a buy rating at Sterne Agee. $17 price target. In the third inning of a long-term turnaround, Sterne Agee said.

Lakes Entertainment ( LACO) was downgraded to hold at TheStreet Ratings.

Ocean Rig ( ORIG) was downgraded at Credit Suisse to neutral from outperform. Upside is limited given the stock's recent run, even as management returns cash to shareholders, Credit Suisse said. Price target is $19.

PAREXEL ( PRXL) was initiated with a neutral rating at Sterne Agee. $44 price target. Successfully climbed PIII CRO market share ladder, Sterne Agee said.

Boston Beer ( SAM) was upgraded at Goldman Sachs to neutral from sell. $162 target price. Near-term volume upside potential, Goldman said.

Texas Roadhouse ( TXRH) was initiated with a buy rating at Bank of America/Merrill Lynch. $28 price target. Well-established brand with attractive valuation, BofA/Merrill said.

STOCK COMMENTS/EPS CHANGES

Aegerion Pharmaceuticals ( AEGR) price target was raised to $88 at J.P. Morgan. Encouraging physician feedback and the recent approval recommendation for Lojuxta have improved the valuation outlook, J.P. Morgan said.

Airgas ( ARG) estimates were reduced at Jefferies. Slow start to the year and weak construction demand, said Jefferies.

Cardinal Health ( CAH) price target was raised at Credit Suisse to $55. Contract changes, acquisitions and the evolution of drug distribution environment should be priced in to the stock, Credit Suisse said.

Cytec Industries ( CYT) estimates were raised at Jefferies. Reflects a faster share buyback, said Jefferies.

Macy's ( M) price target was raised of Bank of America/Merrill Lynch to $55. Analyst day highlights long-term growth opportunities, BofA/Merrill said. Reiterate Buy rating.

Navistar ( NAV) price target and estimates were reduced at UBS. Reflect the second-quarter miss and continued warranty expenses, UBS said. Price target decreased to $35.

Spectra Energy ( SE) price target was raised at Deutsche Bank to $36. The company is pursuing the dropdown of all of its U.S. Transmission and Storage assets, said Deutsche Bank.

Tesoro ( TSO) price target and estimates were raised at J.P. Morgan to reflect the Carson refinery acquisition and Bakken intake, said J.P. Morgan. Price target goes to $65.

Ulta ( ULTA) estimates were raised at Oppenheimer to reflect the better-than-expected first-quarter results, said Oppenheimer.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.